药物性肝损伤如何处理,一文总结

2021-08-05 zyyzjy MedSci原创

药物性肝损伤(DILI)占非病毒性肝病的20%-50%,占急性肝损伤住院患者的20%,是临床上最常见的药物不良反应之一!

药物性肝损伤(drug‑induced liver injury,DILI)的发生率为1.4% -8.1%,占非病毒性肝病的20%-50%,占急性肝损伤住院患者的20%,是临床上最常见的药物不良反应之一,若治疗不及时,可进展为肝衰竭,危及生命,所以也是最严重的药物不良反应之一,因此临床上应加以重视。

1.哪些药物可引起肝损伤?

1)目前明确引起DILI的药物超过1000种,包括非甾体类抗炎药、抗感染药物(含抗结核药物)、抗肿瘤药、中枢神经系统用药、血管系统用药、代谢性疾病用药、激素类药物、生物制剂、传统中药、天然药、保健品、膳食补充剂等,其中中药、膳食补充剂及抗结核药是我国DILI的主要原因,对乙酰氨基酚是引起急性肝衰竭最主要的原因。

2.DILI分类

1)根据发生的可预见性分类:

导致DILI的药物分为可预测性和不可预测性两类;

①可预测性药物是指一旦过量或超长疗程使用该药物,大多数人出现肝损伤,呈剂量、疗程依赖性,代表性药物有对乙酰氨基酚、胺碘酮、环磷酰胺、环孢素、甲氨蝶呤等;

②不可预测性药物是指肝损伤程度与药物剂量和疗程无关,常发生在一些过敏或代谢特异体质的患者,由机体免疫介导;

大多数药物引起的DILI是不可预测的。此外值得注意的是不同药物可导致相同类型肝损伤,同一种药物也可导致不同类型的肝损伤。

2)按病程分:

①急性DILI:

DILI发生6个月内,肝功能恢复正常,无明显影像学和组织学肝功能损伤证据。其占DILI的90%以上,多发生在用药后的第5-90天。

②慢性DILI:

DILI发生6个月后,血清 ALT、AST、ALP 及TBil仍持续异常,或存在门静脉高压或慢性肝损伤的影像学和组织学证据。

3)按受损靶细胞分:

图片

注:R=血清(ALT实测值/ALT的正常值上限ULN/ALP实测值/ALPULN

3.DILI有哪些危险因素?

①宿主因素:分为遗传因素和非遗传因素,包括高龄、女性、妊娠、饮酒、联合使用药物、合并慢性肝病、合并艾滋病等。

②药物因素:包括药物的化学性质、剂量、疗程、药物相互作用、中药材种植和炮制等过程中的污染等常可影响DILI的潜伏期、临床类型、病程和结局。

③环境因素:过量饮酒可能增加度洛西汀、对乙酰氨基酚、甲氨蝶呤及异烟肼等引起DILI的风险。吸烟对DILI易感性的影响尚不清楚。

4. DILI的诊断

①有药物暴露史;

②排除其他原因或疾病所致的肝功能损伤;

③可能有危险因素和药物说明书含有肝毒性信息;

④肝脏损伤在相应的潜伏期,通常1-4周;

⑤停药后,肝功能指标有所改善;

⑥偶尔再次给药,迅速激发肝损伤。

其中①②是诊断DILI的必要条件,③-⑥是非必要条件。

5. DILI严重程度分级

图片

6. DILI的治疗

1)基本治疗原则:

①及时停用可疑肝损伤药物,尽量避免再次使用可疑或同类药物;

②应充分权衡停药引起原发病进展和继续用药导致肝损伤加重的风险;

③根据DILI的临床类型选用适当的药物治疗;

④重症患者必要时可考虑紧急肝移植。

2)停药

出现下列情况之一应考虑停用肝损伤药物:

①血清ALT或AST>8倍ULN;

②ALT或AST>5倍ULN,持续2周;

③ALT或AST>3倍ULN,且TBil>2倍ULN或INR>1.5;

④ALT或AST>3倍ULN,伴逐渐加重的疲劳、恶心、呕吐、右上腹疼痛或压痛、发热、皮疹和/或嗜酸粒细胞增多(>5%)。

多数患者在停用肝损伤药物后可完全恢复。

3)保肝药物:

图片

 4)保肝药物选择原则:

①简化用药。最好选择1种具有多重作用机制的药物,必要时可考虑不同作用机制的药物联用。

②选择疗效确切的药物。

③大多数药物以口服途径用药,肝功能衰竭时静脉给药为主,也可静脉滴注后改为口服的序贯治疗。

④注重药物安全性。用药期间应定期观察患者的症状、体征和肝功能变化,必要时及时调整用药方案。

5)急性肝衰竭治疗:

重症DILI一旦患者发生急性肝衰竭且经内科治疗不能逆转或预后凶险,应及时行人工肝支持或肝移植治疗。

7.预后

急性DILI患者大多预后良好。

慢性DILI的预后总体上好于组织学类型相似的非药物性慢性肝损伤。

胆汁淤积型DILI一般在停药3个月-3年恢复;

少数患者病情迁延,可导致胆汁淤积性肝硬化,预后不良。

药物性急性/亚急性肝衰竭病死率高。

参考文献:
1.血液病患者药物性肝损伤的预防和规范化治疗专家共识(2016年版)中华血液学杂志2016年6月第37卷第6期
2.恶性血液病患者药物性肝损伤的预防和规范化治疗中国专家共识(2021年版)中华血液学杂志2021年3月第42卷第3期
3.药物性肝损伤基层诊疗威廉亚洲博彩公司 (2019年)中华全科医师杂志 2020 年10月第 19卷第10期
4.药物性肝损伤诊治威廉亚洲博彩公司 实用肝脏病杂志2017年 2 月第 20卷第 2 期

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
    2024-07-23 ms2000001420805583 来自陕西省

    这份分享有年头了,但仍有学习的意义

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
    2021-09-13 GXXHCC

    👍🏻

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
    2021-08-20 125986e5m19暂无昵称

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
    2021-08-11 1e1ad8bdm04(暂无匿称)

    学习啦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
    2021-08-05 1e1606abm78(暂无匿称)

    很有临床指导意义

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
    2021-08-05 zhangwangwei

    非常详细实用

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2216368, encodeId=22052216368e9, content=这份分享有年头了,但仍有学习的意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=460e9395367, createdName=ms2000001420805583, createdTime=Tue Jul 23 01:33:46 CST 2024, time=2024-07-23, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1050031, encodeId=94241050031d5, content=👍🏻, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210911/929dc28967294ffb8d54be661f8f376a/594526cdd98f488e818e6adfcd619b8a.jpg, createdBy=214b5528879, createdName=GXXHCC, createdTime=Mon Sep 13 20:07:28 CST 2021, time=2021-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009851, encodeId=de70100985121, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bf62577341, createdName=125986e5m19暂无昵称, createdTime=Fri Aug 20 23:56:17 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006863, encodeId=4b9a1006863d6, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95901993306, createdName=1e1ad8bdm04(暂无匿称), createdTime=Wed Aug 11 09:13:21 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338837, encodeId=a0a9133883e69, content=<a href='/topic/show?id=9d3d812280b' target=_blank style='color:#2F92EE;'>#肝损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81228, encryptionId=9d3d812280b, topicName=肝损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1398179, encodeId=727513981e909, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540093, encodeId=34b3154009361, content=<a href='/topic/show?id=52f28e736c9' target=_blank style='color:#2F92EE;'>#药物性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87736, encryptionId=52f28e736c9, topicName=药物性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sat Aug 07 01:17:11 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005406, encodeId=37751005406ca, content=很有临床指导意义, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/18a80d2367814f61bbe4c923e65f1d98/16479f926d194fa8a9ea5e1f2e022e9b.jpg, createdBy=e1981971406, createdName=1e1606abm78(暂无匿称), createdTime=Thu Aug 05 16:52:12 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005384, encodeId=804e100538410, content=非常详细实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210213/f6efe772e64a4d43a4f84fa895d5563e/03b3c2b9f0cd4e128f02dd2ffc620743.jpg, createdBy=897d1605912, createdName=zhangwangwei, createdTime=Thu Aug 05 15:47:14 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005340, encodeId=63cd100534065, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9bbb5530816, createdName=ms8000002081360713, createdTime=Thu Aug 05 12:45:42 CST 2021, time=2021-08-05, status=1, ipAttribution=)]
    2021-08-05 ms8000002081360713

    学习了

    0

相关威廉亚洲官网

Gastroenterology:药物性肝损伤患者死亡风险影响因素研究

共病负担、终末期肝病评分和血清白蛋白水平是预测疑似DILI患者6个月的死亡率重要因素

2021年恶性血液病患者药物性肝损伤防治共识,3分钟get要点!

在血液系统疾病尤其是恶性血液肿瘤的治疗中,药物性肝损伤(DILI)是最为常见的药源性疾病,而随着抗血液肿瘤药物的研发进展,DILI的临床管理面临新的挑战。

Clin Gastroenterol Hepatol: 血清牛磺胆酸水平高与药物引起的肝损伤的严重程度相关

药物性肝损伤(DILI)是临床上最常见的肝损伤原因之一,DILI可以具有不同的临床特征和参差不齐的预后结果,患者一旦出现黄疸则会导致很高的死亡率。

2019 EASL临床实践威廉亚洲博彩公司 :药物性肝损伤

2019年3月,欧洲肝脏研究学会(EASL)发布了药物性肝损伤威廉亚洲博彩公司 ,特异性药物肝损伤是肝病科医生面临的最具挑战的肝病之一,由于临床实践中药物种类繁多,药物性肝损伤具有多种临床和病理表型,且缺乏特定的生物标志物。本文主要总结了当前关于药物性肝损伤的危险因素、诊断、管理以及最小化风险策略的相关内容并提出指导建议。

研究人员发现治疗药物性肝损伤的新靶标:血小板反应蛋白-1

2019年实验生物学(EB)会议上报道的临床前研究结果表明,增加血小板反应蛋白-1的水平可以减轻过量对乙酰氨基酚诱导的肝损伤。

J Hepatology: 胆红素和碱性磷酸酶升高与药物性肝损伤的恢复时间延长有关

药物性肝损伤(DILI)是一种药物使用后的副作用,尽管大多数 DILI 在停止使用一些药物后会消退,但恢复时间因患者而异,而且6-12% 的病例最终会发展为慢性肝损伤。